Clinical Trial Update: A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating the safety and potential benefit of GSK2982772 in moderate to severe psoriasis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• GSK2982772 (GSK2982772)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Psoriasis | Phase 1 | Status: COMPLETED | Results posted: 2024-03-18